At ESMO 2026, Sun Pharma to Present Long-Term Follow-up Data on UNLOXCYT® (cosibelimab-ipdl) from One of the Largest Prospective Studies in Advanced Cutaneous Squamous Cell Carcinoma (aCSCC)
34% of patients with locally advanced disease achieved a complete response (CR) while 17%-21% of metastatic patients achieved a CR The tolerability profile was consistent with earlier analyses, with a low level of high grade immune-related adverse events MUMBAI, India and HOOFDDORP,...
Extrait seulement — cet éditeur protège son texte. Lisez le communiqué complet à la source.
Forfait Gratuit · Plus 29 $ CA ou Pro 99 $ CA/mois


